PL3164393T3 - Pochodne flawaglin - Google Patents

Pochodne flawaglin

Info

Publication number
PL3164393T3
PL3164393T3 PL15733767T PL15733767T PL3164393T3 PL 3164393 T3 PL3164393 T3 PL 3164393T3 PL 15733767 T PL15733767 T PL 15733767T PL 15733767 T PL15733767 T PL 15733767T PL 3164393 T3 PL3164393 T3 PL 3164393T3
Authority
PL
Poland
Prior art keywords
flavagline derivatives
flavagline
derivatives
Prior art date
Application number
PL15733767T
Other languages
English (en)
Inventor
Frédéric MARION
El Bachir Kaloun
Frédéric LIEBY-MULLER
Michel Perez
Jean-Philippe Annereau
Laurent Creancier
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of PL3164393T3 publication Critical patent/PL3164393T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
PL15733767T 2014-07-04 2015-07-06 Pochodne flawaglin PL3164393T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1456474A FR3023290B1 (fr) 2014-07-04 2014-07-04 Derives de flavaglines
PCT/EP2015/065294 WO2016001441A1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines
EP15733767.6A EP3164393B1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines

Publications (1)

Publication Number Publication Date
PL3164393T3 true PL3164393T3 (pl) 2019-03-29

Family

ID=52016681

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18187037.9T PL3418273T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin
PL15733767T PL3164393T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18187037.9T PL3418273T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin

Country Status (9)

Country Link
US (2) US10047064B2 (pl)
EP (3) EP3998257A1 (pl)
JP (4) JP6637954B2 (pl)
DK (2) DK3164393T3 (pl)
ES (2) ES2908225T3 (pl)
FR (1) FR3023290B1 (pl)
PL (2) PL3418273T3 (pl)
TR (1) TR201819805T4 (pl)
WO (1) WO2016001441A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180096644A (ko) 2015-11-25 2018-08-29 이펙터 테라퓨틱스, 인크. Eif4a-억제 화합물 및 이에 관련된 방법
MY195426A (en) * 2017-06-19 2023-01-20 Futurechem Co Ltd 18f-Labelled Compound for Prostate Cancer Diagnosis, and use Thereof
JP2021513963A (ja) * 2018-02-19 2021-06-03 メモリアル スローン ケタリング キャンサー センター 異常増殖性疾患を治療するための薬剤および方法
US11427595B2 (en) * 2018-10-22 2022-08-30 Trustees Of Boston University Compositions and methods for inhibiting viral infection
WO2021072300A1 (en) * 2019-10-10 2021-04-15 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
CA2652873A1 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
BRPI0922938A2 (pt) 2008-12-05 2017-06-06 Intermed Discovery Gmbh inibidores de acúmulo de proteína hif-1

Also Published As

Publication number Publication date
JP6637954B2 (ja) 2020-01-29
DK3164393T3 (en) 2019-01-21
JP6951406B2 (ja) 2021-10-20
US20180086729A1 (en) 2018-03-29
FR3023290A1 (fr) 2016-01-08
WO2016001441A1 (fr) 2016-01-07
US20170137400A1 (en) 2017-05-18
JP2023159393A (ja) 2023-10-31
JP7340574B2 (ja) 2023-09-07
EP3998257A1 (fr) 2022-05-18
ES2700156T3 (es) 2019-02-14
EP3164393A1 (fr) 2017-05-10
PL3418273T3 (pl) 2022-08-01
EP3418273A1 (fr) 2018-12-26
FR3023290B1 (fr) 2016-08-19
JP2020063289A (ja) 2020-04-23
EP3164393B1 (fr) 2018-09-19
US10047064B2 (en) 2018-08-14
ES2908225T3 (es) 2022-04-28
TR201819805T4 (tr) 2019-01-21
DK3418273T3 (da) 2022-03-21
JP2017519796A (ja) 2017-07-20
US10519125B2 (en) 2019-12-31
JP2022000455A (ja) 2022-01-04
EP3418273B1 (fr) 2022-01-12

Similar Documents

Publication Publication Date Title
IL253381B (en) History of h9–pyrrolo–dipyridine
ZA201704602B (en) Dihydroindolizinone derivative
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
PL3164393T3 (pl) Pochodne flawaglin
PL3097076T3 (pl) Nowe pochodne CYP-eikozanoidowe
IL251005B (en) Pyrido-oxazinone derivatives
IL248772A0 (en) A consequence of cyclohexyl pyridine
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
AU5585P (en) Lanutah Mandevilla sanderi
AU2014264V (en) FlatGL Templetonia retusa
GB201412962D0 (en) Swimscarf
GB201410475D0 (en) Portaveg
GB201408788D0 (en) FutureGoal
GB201402693D0 (en) Mac-X
GB201401935D0 (en) EDS-Plus